REG - Diaceutics PLC - Diaceutics Opens US Headquarters

DiaceuticsAnnouncement

14/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250114:nRSN1647Ta&default-theme=true

RNS Number : 1647T  Diaceutics PLC  14 January 2025

Diaceutics Opens US Headquarters

 

New US office in New Jersey will facilitate growth of local sales &
marketing teams close to Diaceutics' pharma customers

 

New York, Belfast and London, 14 January 2025 - Diaceutics PLC (AIM: DXRX), a
leading technology and solutions provider to the pharma and biotech industry,
is pleased to announce that it has opened its new US Headquarters (HQ) in
Newport, New Jersey, in close proximity to the majority of its Life Science
customers in the Northeastern US.

 

The US market represents around 90% of Diaceutics' revenue and the new US HQ
will facilitate the further expansion of its US focused sales & marketing
operations and follows on from the successful recruitment of a number of
senior sales personnel in the US during 2024. Diaceutics' US HQ will provide a
commercial hub, with associated facilities, for all the Company's US based
personnel and will accommodate non-US based personnel whilst they are
travelling in the US.

 

The planned expansion of Diaceutics' US sales and marketing operations will
lead to a significant number of new commercially focused personnel joining the
team, with the majority based at the US HQ.

 

As Diaceutics continues to grow its US business, and in particular rolls out
its full toolkit of pharma and biotech commercialisation solutions, the
geographical location of customer facing teams is essential given the level of
partnership and collaboration between the Company and its customers.

 

Madeline Brown, VP Chief of Staff at Diaceutics, commented: "The US market is
crucial to our future growth plans and we are excited to continue to grow our
business and presence in the US. In 2024, we have had significant success
recruiting senior US based sales and management personnel, and opening our US
HQ enables us to deepen our partnerships with US based life science
customers."

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGGDBUBBDGUX